Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


23.10.2017

1 AJR Am J Roentgenol
2 Br J Radiol
2 Cancer
1 Cancer Res
1 Clin Med Insights Oncol
1 Endocrinology
6 Eur Urol
2 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 Int J Urol
2 J Natl Cancer Inst
1 J Nucl Med
1 J Urol
2 Lancet Oncol
1 Nat Rev Urol
3 Oncol Rep
2 PLoS One
1 Prostate
1 Radiology
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. TAMADA T, Huang C, Ream JM, Taffel M, et al
    Apparent Diffusion Coefficient Values of Prostate Cancer: Comparison of 2D and 3D ROIs.
    AJR Am J Roentgenol. 2017 Oct 18:1-5. doi: 10.2214/AJR.17.18495.
    PubMed     Text format     Abstract available


    Br J Radiol

  2. PIZARRO F, Hernandez A
    Optimization of radiotherapy fractionation schedules based on radiobiological functions.
    Br J Radiol. 2017;90:20170400.
    PubMed     Text format     Abstract available

  3. KWON MR, Kim CK, Kim JH
    PI-RADS version 2: Evaluation of diffusion-weighted imaging interpretation between B = 1000 and B = 1500 s/mm2.
    Br J Radiol. 2017 Aug 22:20170438. doi: 10.1259/bjr.20170438.
    PubMed     Text format     Abstract available


    Cancer

  4. COLLINS GS, Le Manach Y
    Nomograms need to be presented in full.
    Cancer. 2017;123:177-178.
    PubMed     Text format    

  5. BORZA T, Kaufman SR, Yan P, Herrel LA, et al
    Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31081.
    PubMed     Text format     Abstract available


    Cancer Res

  6. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
    Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
    Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
    PubMed     Text format     Abstract available


    Clin Med Insights Oncol

  7. WANG A, Karunasinghe N, Plank L, Zhu S, et al
    Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.
    Clin Med Insights Oncol. 2017;11:1179554917733449.
    PubMed     Text format     Abstract available


    Endocrinology

  8. SARMENTO-CABRAL A, L-Lopez F, Luque RM
    Adipokines and Their Receptors Are Widely Expressed and Distinctly Regulated by the Metabolic Environment in the Prostate of Male Mice: Direct Role Under Normal and Tumoral Conditions.
    Endocrinology. 2017;158:3540-3552.
    PubMed     Text format     Abstract available


    Eur Urol

  9. PLOUSSARD G
    Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30841.
    PubMed     Text format    

  10. SPAHN M
    Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    Eur Urol. 2017 Oct 12. pii: S0302-2838(17)30843.
    PubMed     Text format    

  11. WALLIS CJD, Klaassen Z, Bhindi B, Goldberg H, et al
    Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30849.
    PubMed     Text format     Abstract available

  12. MCLEOD DG, Petrovics G
    Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Eur Urol. 2017 Oct 13. pii: S0302-2838(17)30845.
    PubMed     Text format    

  13. TOUIJER KA, Karnes RJ, Passoni N, Sjoberg DD, et al
    Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30828.
    PubMed     Text format     Abstract available

  14. VAN DER KWAST T
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology.
    Eur Urol. 2017 Oct 14. pii: S0302-2838(17)30842.
    PubMed     Text format    


    Int J Cancer

  15. SEIKKULA HA, Kaipia AJ, Ryynanen H, Seppa K, et al
    The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31109.
    PubMed     Text format     Abstract available

  16. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. PICKLES T, Tyldesley S, Hamm J, Virani SA, et al
    Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.
    Int J Radiat Oncol Biol Phys. 2017 Sep 4. pii: S0360-3016(17)33839.
    PubMed     Text format     Abstract available

  18. KERSHAW L, van Zadelhoff L, Heemsbergen W, Pos F, et al
    Image Guided Radiation Therapy Strategies for Pelvic Lymph Node Irradiation in High-Risk Prostate Cancer: Motion and Margins.
    Int J Radiat Oncol Biol Phys. 2017 Sep 8. pii: S0360-3016(17)33841.
    PubMed     Text format     Abstract available


    Int J Urol

  19. MITSUZUKA K, Arai Y
    Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Int J Urol. 2017 Oct 20. doi: 10.1111/iju.13473.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  20. BROUGHMAN JR, Basak R, Nielsen ME, Reeve BB, et al
    Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.
    J Natl Cancer Inst. 2017 Oct 16. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    J Nucl Med

  22. KRATOCHWIL C, Bruchertseifer F, Rathke H, Bronzel M, et al
    Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
    J Nucl Med. 2017;58:1624-1631.
    PubMed     Text format     Abstract available


    J Urol

  23. AUDENET F, Vertosick EA, Fine SW, Sjoberg DD, et al
    Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77714-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Lancet Oncol

  24. BEER TM, Hotte SJ, Saad F, Alekseev B, et al
    Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international
    Lancet Oncol. 2017 Oct 9. pii: S1470-2045(17)30605.
    PubMed     Text format     Abstract available

  25. AGGARWAL R
    Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer.
    Lancet Oncol. 2017 Oct 9. pii: S1470-2045(17)30718.
    PubMed     Text format    


    Nat Rev Urol

  26. THOMA C
    Prostate cancer: The importance of the mitochondrial genome.
    Nat Rev Urol. 2017 Oct 17. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  27. KOU B, Liu W, Zhao W, Duan P, et al
    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-beta/Smad2/3 signaling pathway.
    Oncol Rep. 2017 Oct 2. doi: 10.3892/or.2017.6012.
    PubMed     Text format     Abstract available

  28. NOWACKA-ZAWISZA M, Wisnik E
    DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5972.
    PubMed     Text format     Abstract available

  29. ZHOU Y, Gu P, Li J, Li F, et al
    Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.
    Oncol Rep. 2017 Sep 18. doi: 10.3892/or.2017.5961.
    PubMed     Text format     Abstract available


    PLoS One

  30. ARTHURS C, Murtaza BN, Thomson C, Dickens K, et al
    Expression of ribosomal proteins in normal and cancerous human prostate tissue.
    PLoS One. 2017;12:e0186047.
    PubMed     Text format     Abstract available

  31. HEBBRECHT T, Van Audenhove I, Zwaenepoel O, Verhelle A, et al
    VCA nanobodies target N-WASp to reduce invadopodium formation and functioning.
    PLoS One. 2017;12:e0185076.
    PubMed     Text format     Abstract available


    Prostate

  32. WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
    The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
    Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
    PubMed     Text format     Abstract available


    Radiology

  33. VERMA S, Choyke PL, Eberhardt SC, Oto A, et al
    The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer.
    Radiology. 2017;285:343-356.
    PubMed     Text format     Abstract available


    Urology

  34. NGUYEN A, O'Leary MP
    Re: Deebel et al.: Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges (Urology 2017, http://dx.doi.org/doi:10.1016/j.urology.2017.08.032).
    Urology. 2017 Oct 16. pii: S0090-4295(17)31076.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: